ES2610158T3 - Nuevos inhibidores pirrólicos de S-nitrosoglutatión reductasa como agentes terapéuticos - Google Patents
Nuevos inhibidores pirrólicos de S-nitrosoglutatión reductasa como agentes terapéuticos Download PDFInfo
- Publication number
- ES2610158T3 ES2610158T3 ES09807378.6T ES09807378T ES2610158T3 ES 2610158 T3 ES2610158 T3 ES 2610158T3 ES 09807378 T ES09807378 T ES 09807378T ES 2610158 T3 ES2610158 T3 ES 2610158T3
- Authority
- ES
- Spain
- Prior art keywords
- aryl
- nre
- phenyl
- heteroaryl
- unsubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/402—1-aryl substituted, e.g. piretanide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/323—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
- C07D207/327—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/337—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
Un compuesto de formula I o una sal farmaceuticamente aceptable del mismo:**Fórmula** en la que Ar se selecciona entre el grupo que consiste en arilo, arilo sustituido, heteroarilo y heteroarilo sustituido, en donde el arilo es un sistema de anillo aromatico monociclico, biciclico o triciclico de 5 a 14 miembros; y el heteroarilo es un anillo heterociclo aromatico de 5 a 14 miembros que tiene al menos un heteroatomo seleccionado entre nitrogeno, oxigeno y azufre, que contiene al menos 1 atomo de carbono, incluyendo sistemas de anillo monociclicos, biciclicos y tricicicos, en donde los sustituyentes para arilo y heteroarilo se seleccionan entre el grupo que consiste en: -halo, -ORe', -OC(O)Re', -NRe'Re", -SRe', -Re', -CN, -NO2, -CO2Re', -C(O)NRe'Re" -C(O)Re', -OC(O)NRe'Re", -NRe"C(O)Re', -NRe"CO2Re', -NRe"'C(O)NRe'Re", -NRe'"SO2NRe'Re", - NHC(NH2)>=NH, -NRe'C(NH2)>=NH, -NH-C(NH2)>=NRe', -S(O)Re', -SO2Re', -SO2NRe'Re", -NRe"SO2Re', -N3, -CH(Ph)z, perfluoroalcoxi y perfluoroalquilo(C1-C4), en un numero que varia de cero al numero total de valencias abiertas en el sistema de anillo aromatico; y donde Re', Re" y Re"' se seleccionan independientemente entre hidrogeno, alquilo (C1-C8) no sustituido, heteroalquilo (C1-C8) no sustituido, arilo no sustituido, heteroarilo no sustituido, arilalquilo (C1-C4) no sustituido, ariloxialquilo (C1-C4) no sustituido, arilo monosustituido y heteroarilo monosustituido; R1 se selecciona entre el grupo que consiste en hidrogeno, alquilo C1-C6, cicloalquilo C3-C6, arilo, arilo sustituido, heteroarilo y heteroarilo sustituido, en donde arilo, heteroarilo y los sustituyentes para arilo y heteroarilo son como se han definido anteriormente; R2 se selecciona entre el grupo que consiste en halogeno, alquilo C1-C6, cicloalquilo C3-C6, ciano, nitro, CF3, carbamoilo, alquilcarbamoilo C1-C6, amino, alquilamino C1-C6, dialquilamino C1-C6, alcoxi C1-C6 y cicloalcoxilo C3-C6; R3 se selecciona entre el grupo que consiste en hidroxilo, carbamoilo, alquilcarbamoilo C1-C6, sulfamoilo, alquilsulfamoilo C1-C6, cicloalquilo C3-C6, ciano, nitro, carboxilo, amino, aminometilo, acetamido, acetamido-2-metilo, 2-metoxiacetamido, propionamido, tetrahidrofurano-2-ilmetoxi, CF3, carboxilo, ureido, sulfamoilamino, alquilsulfonamido C1-C6, 2-amino-2-oxoetilo, alquilamino C1-C6, dialquilamino C1-C6, arilamino, 30 heteroarilamino, alcoxilo C1-C6, cicloalcoxilo C3-C6, 1H-imidazol-2-ilo, oxazol-2-ilo, tiazol-2-ilo, metilcarbamoilo, dimetilcarbamoilo, metoxietilcarbamoilo, hidroxietilcarbamoilo, (dimetilamino)etilcarbamoilo, piridin-3-ilcarbamoilo, piridin-4-il-carbamoilo, 6-metoxipiridin-3-ilcarbamoilo, piridazin-4-ilcarbamoilo y pirimidin-5-il- carbamoilo; R4 se selecciona entre el grupo que consiste en hidrogeno, hidroxilo, halogeno, alquilo C1-C6, cicloalquilo C3-C6, ciano, nitro, carbamoilo, alquilcarbamoilo C1-C6, sulfamoilo, alquil C1-C6 sulfamoilo, amino, alquilamino C1-C6, dialquilamino C1-C6, alcoxilo C1-C6 y cicloalcoxilo C3-C6; n es 0-3; en donde Ar excluye indazol-3-ilo sustituido o no sustituido y 1H-pirazolo[3,4-b]piridilo sustituido o no sustituido; con las siguientes condiciones: condicion Ia: cuando R3 es carboxilo, metilsulfonamido o sulfamoilo, entonces Ar no puede ser fenilo, fenilalquilo (C1-C3) sustituido o no sustituido o fenil-alquenilo (C2-C6); y condicion Ib: cuando R2 y R3 son ambos metoxi, entonces Ar no puede ser fenilo, 4-metil-fenilo, 4-metoxi-fenilo, 4-halo-fenilo o tiofenilo.
Description
de acuerdo con la reivindicación 1.
En realizaciones de la invención de fórmula I, Ar se selecciona entre el grupo que consiste en fenilo, fenilo sustituido,
5 tiofenilo, tiofenilo sustituido, piridinilo, piridinilo sustituido, tiazolilo, tiazolilo sustituido, pirimidinilo, pirimidinilo sustituido, furanilo, furanilo sustituido, arilo bicíclico, arilo bicíclico sustituido, heteroarilo bicíclico y heteroarilo bicíclico sustituido; R1 se selecciona entre el grupo que consiste en hidrógeno y alquilo C1-C6; R2 se selecciona entre el grupo que consiste en halógeno, alquilo C1-C6 y CF3; R3 se selecciona entre el grupo que consiste en hidroxilo, carbamoílo, sulfamoílo, sulfamoilamino, alcoxi C1-C6, amino,
10 aminometilo, acetamido, acetamido-2-metilo, 2-metoxiacetamido, propionamido, tetrahidrofurano-2-ilmetoxi, metilsulfamido, carboxilo, alquilamino C1-C6, 1H-imidazol-2-ilo, oxazol-2-ilo, tiazol-2-ilo, metilcarbamoílo, dimetilcarbamoílo, metoxietilcarbamoílo, hidroxietilcarbamoílo, (dimetilamino)etilcarbamoílo, piridin-3-ilcarbamoílo, piridin-4-il-carbamoílo, 6-metoxipiridin-3-ilcarbamoílo, piridazin-4-ilcarbamoílo y pirimidin-5-ilcarbamoílo; R4 se selecciona entre el grupo que consiste en hidrógeno y alquilo C1-C6;y
15 nes1.
En realizaciones de la invención de fórmula I, Ar se selecciona entre el grupo que consiste en fenilo, fenilo sustituido, aril-fenilo, aril-fenilo sustituido, heteroaril-fenilo, heteroaril-fenilo sustituido, tiofenilo, tiofenilo sustituido, aril-tiofenilo, aril-tiofenilo sustituido, heteroaril-tiofenilo, heteroaril-tiofenilo sustituido, piridinilo, piridinilo sustituido, aril-piridinilo,
20 aril-piridinilo sustituido, heteroaril-piridinilo, heteroaril-piridinilo sustituido, tiazolilo, tiazolilo sustituido, aril-tiazolilo; aril-tiozolilo sustituido; heteroaril-tiazolilo; heteroaril-tiazolilo sustituido, pirimidinilo, pirimidinilo sustituido, aril-pirimidinilo, aril-pirimidinilo sustituido, heteroaril-pirimidinilo, heteroaril-pirimidinilo sustituido, furanilo, furanilo sustituido, aril-furanilo, aril-furanilo sustituido, heteroaril-furanilo y heteroaril-furanilo sustituido.
25 En realizaciones de la invención de fórmula I, Ar es fenilo, tiofenilo, tiazolilo, piridinilo, pirimidinilo o furanilo que tiene 0, 1, 2 o 3 sustituciones, en el que tales sustituciones se seleccionan independientemente entre el grupo que consiste en hidrógeno, hidroxilo, halógeno, alcoxi C1-C6, amino, ciano, alquilo C1-C6, imidazolilo, metil imidazolilo, etil imidazolilo, furanilo, metiltio, nitro, triazolilo, tetrazolilo, carbamoílo, pirazolilo, trifluorometoxi, trifluorometilo, 2-amino-2oxoetoxi, ureido, morfolino, piridinilo, pirrolilo, metil sulfonamido, carbamoil fenilo, 6-oxo-1,6-dihidropiridinilo,
30 3,5-dimetilisoxazolilo, carboximatoxi, hidroxiacetamido, metoxiacetamido, sulfamoílo, piperazinilo, oxoimidazolidinilo, metilsulfinilo, metilsulfonilo, pirrolidinilo, piperidinilo, metilpirazolilo, fenilo, tiazolilo, hidroxicarbamoílo, ciclopropilimidazolilo, carboxi, metilamino, metoximetilo, dimetilamino, hidroximetilimidazolilo, oxooxazolidinilo, formamido, hidroxifenilo y tiofenilo.
35 En realizaciones de la invención de fórmula I, Ar se selecciona entre el grupo que consiste en 4-(1H-imidazol-1-il)fenilo, 5-(1H-imidazol-1-il)tiofen-2-ilo, 4-(2-metil-1H-imidazol-1-il)fenilo, tiazol-5-ilo, 4-hidroxifenilo, 5-bro-motiofen-2-ilo, 4-metoxifenilo, 4-aminofenilo, 4-bromofenilo, 4-(furan-3-il)fenilo, fenilo, 3-cloro-4-metoxifenilo, 3-fluoro-4-metoxifenilo, 4-cianofenilo, 3-cloro-4-hidroxifenilo, 4-metoxi-3-metilfenilo, 4-yodofenilo, 3-metoxifenilo, 6-metoxipiridin-3-ilo, benzo[d]tiazol-6-ilo, 4-(metiltio)fenilo, 4-nitrofenilo, 4-(4H-1,2,4-triazol-4-il)fenilo, 4-(2H-tetrazol-5-il)fenilo,
40 benzo[d][1,3]dioxol-5-ilo, 6-(1H-imidazol-1-il)piridin-3-ilo, 5-carbamoiltiofen-2-ilo, 4-(1H-pirazol-4-il)fenilo, 4-(trifluorometoxi)fenilo, 4-carbamoilfenilo, 4-(trifluorometil)fenilo, 4-(1H-1,2,4- triazol-1-il)fenilo, 4-(1H-pirazol-1-il)fenilo, 4-(2-amino-2-oxoetoxi)fenilo, 4-(1-metil-1H-pirazol-4-il)fenilo, 4-(1H-tetrazol-1-il)fenilo, 4-(4-metil-1H-imidazol-1-il)fenilo, 4-ureidofenilo, 4-morfolinofenilo, 4-(2H-tetrazol-5-il)fenilo, 4-(piridin-4-il)fenilo, 4-(1H-pirrol-1-il)fenilo, 4-(metilsulfonamido)fenilo, 1H-1,2,3-triazol-1-il)fenilo, naftalen-2-ilo, 3’-carbamoilbifenil-4-ilo,
45 4-(6-oxo-1,6-dihidropiridin-3-il)fenilo, 4-(3,5-dimetilisoxazol-4-il)fenilo, 4-(piridin-3-il)fenilo, 4-(carboximatoxi)fenilo, 4-(2-hidroxiacetamido)fenilo, 4-(2-metoxiacetamido)fenilo, 4-sulfamoilfenilo, 4-(piperazin-1-il)fenilo, 4-(2-oxoimidazolidin-1-il)fenilo, 4-etoxifenilo, 4-(metilsulfinil)fenilo, 4-(2-etil-1H-imidazol-1-il)fenilo, 4-(furan-2-il)fenilo, 4-(metilsulfonil)fenilo, 4-(pirrolidin-1-il)fenilo, 4-(piperidin-1-il)fenilo, 4-(1-metil-1H-pirazol-5-il)fenilo, 5-(2-metil-1H-imidazol-1-il)tiofen-2-ilo, 4-(furan-3-il)fenilo, 2-metoxipirimidin-5-ilo, 2-metil-4-(metilsulfonamido)fenilo,
50 4-amino-3-clorofenilo, 3,4-difluorofenilo, 2,4-difluorofenilo, 4-clorofenilo, 4-bromotiofen-2-ilo, bifenil-4-ilo, 2-(1H-imidazol-1-il)pirimidin-5-ilo, 4-fluoro-3-metoxifenilo, 3-ciano-4-fluorofenilo, 4-carbamoil-2-metilfenilo, 4-metoxi-2-metilfenilo, 4-cloro-2-fluorofenilo, 4-fluorofenilo, 4-fluoro-2-metilfenilo, 4-cloro-2-(trifluorometil)fenilo, 4-cloro-2-metoxifenilo, 4-ciano-3-fluorofenilo, 2-cloro-4-metoxifenilo, 4-(1H-imidazol-1-il)tiofen-2-ilo, 3,5-dimetil-4-nitrofenilo, 4-amino-3,5-dimetilfenilo, 2-(1H-imidazol-1-il)tiazol-4-ilo, 2-etoxi-4-fluorofenilo,
10
Se debe observar que algunos isómeros que surgen a partir de tal asimetría (por ejemplo, todos los enantiómeros y diastereómeros) están incluidos dentro del alcance de la invención, a menos que se indique de otro modo. tales isómero se pueden obtener en forma sustancialmente pura mediante técnicas clásicas de separación y mediante síntesis controlada de forma estereoquímica. Además, las estructuras y otros compuestos y restos que se analizan en
5 la presente solicitud también incluyen todos los tautómeros de los mismos. Algunos alquenos pueden incluir, cuando sea apropiado, cualquiera de las geometrías E o Z.
2. Inhibidores de GSNOR representativos
10 La Tabla 1 que sigue a continuación enumera nuevos análogos de pirrol representativos de Fórmula I útiles como inhibidores de GSNOR de la invención. Los métodos sintéticos que pueden usarse para preparar cada uno de los compuestos, identificados en la Tabla 1 (es decir Esquema 1, Esquema 2, etc.) se detallan más adelante. En algunos casos, si el material de partida o intermedio de un esquema no está disponible en el mercado, entonces un método correspondiente (llamado Método 1, Método 2, etc.) describe la síntesis de ese material de partida o intermedio. La
15 Tabla 1 proporciona el número de Esquema, define los materiales de partida mostrados en los Esquemas y donde es necesario proporciona el número de método que se corresponde a la síntesis de un intermedio o material de partida. En la Tabla 1 también se incluyen datos de espectrometría de masas de apoyo para cada compuesto. La actividad del inhibidor de GSNOR se determinó mediante el ensayo que se describe en el Ejemplo 2 y se obtuvieron valores de CI50 se obtuvieron. Los compuestos inhibidores de GSNOR 1-198 de la Tabla 1 tuvieron un CI50 de aproximadamente
20 <100 µM. Los compuestos inhibidores de GSNOR 1-42, 69-71, 73-77, 79-81, 84-86, 92-103, 105-108, 110, 112-118, 120, 123-142, 144-164, 166-168, 170-172, 175-181, 183, 185-198 de la Tabla 1 tuvieron un CI50 de aproximadamente inferior a 5,0 µM. Los compuestos inhibidores de GSNOR 1-25, 69, 75-76, 80, 84-86, 92-94, 96-99, 101-103, 105-106, 110, 112-116, 118, 120, 124-126, 128-131, 133-137, 139-141, 144, 146, 149-150, 152, 154-157, 162-163, 166-168, 170-172, 175-180, 186-192, 194 y 196-197 de la Tabla 1 tuvieron un valor de CI50 de aproximadamente inferior a
25 1,0 µM.
13
14
15
19
Claims (1)
-
imagen1 imagen2 imagen3 imagen4 imagen5 imagen6 imagen7 imagen8 imagen9 imagen10 imagen11
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8931308P | 2008-08-15 | 2008-08-15 | |
US89313P | 2008-08-15 | ||
US11698208P | 2008-11-21 | 2008-11-21 | |
US116982P | 2008-11-21 | ||
PCT/US2009/053923 WO2010019903A1 (en) | 2008-08-15 | 2009-08-14 | Novel pyrrole inhibitors of s-nitrosoglutathione reductase as therapeutic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2610158T3 true ES2610158T3 (es) | 2017-04-26 |
Family
ID=41669340
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES09807378.6T Active ES2610158T3 (es) | 2008-08-15 | 2009-08-14 | Nuevos inhibidores pirrólicos de S-nitrosoglutatión reductasa como agentes terapéuticos |
ES09807383.6T Active ES2572615T3 (es) | 2008-08-15 | 2009-08-14 | Nuevos inhibidores pirrólicos de S-nitrosoglutatión reductasa como agentes terapéuticos |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES09807383.6T Active ES2572615T3 (es) | 2008-08-15 | 2009-08-14 | Nuevos inhibidores pirrólicos de S-nitrosoglutatión reductasa como agentes terapéuticos |
Country Status (23)
Country | Link |
---|---|
US (7) | US8673961B2 (es) |
EP (3) | EP3069721A1 (es) |
JP (4) | JP2012500216A (es) |
KR (1) | KR20110042364A (es) |
CN (1) | CN102186478B (es) |
AU (1) | AU2009281747B2 (es) |
BR (1) | BRPI0917017B8 (es) |
CA (1) | CA2734154C (es) |
CY (2) | CY1117524T1 (es) |
DK (2) | DK2315591T3 (es) |
ES (2) | ES2610158T3 (es) |
HK (2) | HK1156540A1 (es) |
HR (2) | HRP20160658T1 (es) |
HU (2) | HUE031580T2 (es) |
IL (1) | IL211056A (es) |
LT (1) | LT2318006T (es) |
PL (2) | PL2315591T3 (es) |
PT (1) | PT2318006T (es) |
RU (1) | RU2500668C2 (es) |
SI (2) | SI2315591T1 (es) |
SM (2) | SMT201600177B (es) |
WO (2) | WO2010019910A1 (es) |
ZA (1) | ZA201100966B (es) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8455513B2 (en) | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
US8450344B2 (en) | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
HUE031580T2 (en) | 2008-08-15 | 2017-07-28 | Nivalis Therapeutics Inc | New pyrrole inhibitors of S-nitrosoglutathion reductase as therapeutic agents |
WO2010019905A1 (en) | 2008-08-15 | 2010-02-18 | N30 Pharmaceuticals, Llc | Novel pyrrole inhibitors of s-nitrosoglutathione reductase as therapeutic agents |
JP5524209B2 (ja) | 2008-08-15 | 2014-06-18 | エヌサーティー・ファーマシューティカルズ・インコーポレーテッド | S−ニトロソグルタチオンレダクターゼのピロール阻害剤 |
EP3053913B1 (en) | 2009-05-01 | 2018-03-07 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
EP2512247B1 (en) * | 2009-12-16 | 2014-06-04 | N30 Pharmaceuticals, Inc. | Novel thiophene inhibitors of s-nitrosoglutathione reductase |
US8946434B2 (en) | 2010-07-16 | 2015-02-03 | N30 Pharmaceuticals, Inc. | Dihydropyridin-2(1H)-one compound as S-nirtosoglutathione reductase inhibitors and neurokinin-3 receptor antagonists |
US8906933B2 (en) | 2010-09-24 | 2014-12-09 | N30 Pharmaceuticals, Inc. | Dihydropyrimidin-2(1H)-one compounds as neurokinin-3 receptor antagonists |
BR112013007907A2 (pt) | 2010-10-08 | 2016-06-14 | N30 Pharmaceuticals Inc | novos compostos de quinolina substituída como inibidores de s-nitrosoglutationa reductase |
AU2011343518B2 (en) | 2010-12-16 | 2016-11-10 | Nivalis Therapeutics, Inc. | Novel substituted bicyclic aromatic compounds as S-nitrosoglutathione reductase inhibitors |
WO2013006658A1 (en) * | 2011-07-05 | 2013-01-10 | The Brigham And Women's Hospital, Inc. | Treatment of acetaminophen-induced liver damage by the administration of modulators of nitric oxide |
US20140113945A1 (en) * | 2011-07-05 | 2014-04-24 | N30 Pharmaceuticals, Inc. | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents for Liver Toxicity |
US9365556B2 (en) | 2012-03-16 | 2016-06-14 | Axikin Pharmaceuticals, Inc. | 3,5-diaminopyrazole kinase inhibitors |
CN109528721B (zh) | 2013-03-15 | 2021-10-01 | 爱瑞制药公司 | 联合治疗 |
NZ631142A (en) | 2013-09-18 | 2016-03-31 | Axikin Pharmaceuticals Inc | Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors |
WO2015067630A1 (de) | 2013-11-08 | 2015-05-14 | Bayer Pharma Aktiengesellschaft | Substituierte uracile und ihre verwendung |
JP2016535769A (ja) | 2013-11-08 | 2016-11-17 | バイエル ファーマ アクチエンゲゼルシャフト | キマーゼ阻害薬としての置換されているウラシル類 |
JP6364967B2 (ja) * | 2014-05-30 | 2018-08-01 | 東ソー株式会社 | ジチエノベンゾジチオフェンの製造方法 |
US9546163B2 (en) | 2014-12-23 | 2017-01-17 | Axikin Pharmaceuticals, Inc. | 3,5-diaminopyrazole kinase inhibitors |
CN104529995B (zh) * | 2014-12-30 | 2016-04-27 | 白银摩尔化工有限责任公司 | 一种空气或纯氧催化氧化溴化氢制备2,3,5-三溴噻吩的方法 |
CN104557656B (zh) * | 2015-01-13 | 2016-06-01 | 佛山市赛维斯医药科技有限公司 | 含卤苯和二烯金刚烷结构的化合物、其制备方法和用途 |
WO2017044766A1 (en) | 2015-09-10 | 2017-03-16 | Nivalis Therapeutics, Inc. | Solid forms of an s-nitrosoglutathione reductase inhibitor |
CN105218397B (zh) * | 2015-09-25 | 2017-05-10 | 济南大学 | 2‑叠氮甲基‑4‑硝基苯甲酰氯的合成方法 |
EP3404021A4 (en) | 2016-01-12 | 2019-09-11 | Nippon Chemiphar Co., Ltd. | VOLTAGE-RELATED T-TYPE CALCIUM CHANNEL INHIBITOR |
US10537557B2 (en) | 2016-01-27 | 2020-01-21 | Case Western Reserve University | Methods of treating respiratory disorders |
KR102375929B1 (ko) | 2016-03-31 | 2022-03-16 | 온크터널 테라퓨틱스, 인코포레이티드. | 인돌린 유사체 및 이의 용도 |
TW201806596A (zh) * | 2016-08-01 | 2018-03-01 | 中央研究院 | 抗病毒劑 |
CA3035566A1 (en) | 2016-08-31 | 2018-03-08 | Aerie Pharmaceuticals, Inc. | Ophthalmic compositions |
US9840468B1 (en) | 2016-12-30 | 2017-12-12 | Aerie Pharmaceuticals, Inc. | Methods for the preparation of 6-aminoisoquinoline |
CN110506037A (zh) | 2017-03-31 | 2019-11-26 | 爱瑞制药公司 | 芳基环丙基-氨基-异喹啉酰胺化合物 |
JP2020100564A (ja) * | 2017-04-03 | 2020-07-02 | 京都薬品工業株式会社 | リードスルー誘導剤およびその医薬用途 |
JP7249508B2 (ja) * | 2017-04-11 | 2023-03-31 | ジーエスエヌオー セラピューティクス, インコーポレイテッド | カルバゾール化合物及びその使用法 |
US10925858B2 (en) | 2017-05-08 | 2021-02-23 | The US Government as represented by the Department of Veterans Affairs | S-nitrosoglutathione (GSNO) and GSNO reductase inhibitors for use in therapy |
US11427563B2 (en) | 2018-09-14 | 2022-08-30 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
CN110015963A (zh) * | 2019-04-12 | 2019-07-16 | 上海优合生物科技有限公司 | 一种2-氯-6-甲基苯胺的制备方法 |
US20230357154A1 (en) * | 2019-08-08 | 2023-11-09 | Treventis Corporation | Butyrylcholinesterase compounds and use in diseases of the nervous system |
CN112574193B (zh) * | 2020-12-31 | 2022-05-17 | 南京医科大学 | 一类口服gsnor抑制剂及其药物用途 |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3168528A (en) | 1962-06-14 | 1965-02-02 | Parke Davis & Co | 1-(p-nitrophenyl) and 1-(p-cyanophenyl)-5-arylpyrrole-2-propionic acid compounds |
US3168529A (en) * | 1962-06-14 | 1965-02-02 | Parke Davis & Co | 1-(p-lower alkanoylphenyl)-5-arylpyrrole-2-propionic acid compounds |
US3168527A (en) | 1962-06-14 | 1965-02-02 | Parke Davis & Co | 1-aryl-5-(p-fluorophenyl)-pyrrole-2-propionic acid compounds |
GB997043A (en) | 1962-06-14 | 1965-06-30 | Parke Davis & Co | Derivatives of 1,5-diarylpyrrole-2-propionic acid |
US3168531A (en) | 1963-06-12 | 1965-02-02 | Parke Davis & Co | 1-aryl-5-(p-lower alkoxyphenyl)-pyrrole-2-propionic acid compounds |
US3168532A (en) | 1963-06-12 | 1965-02-02 | Parke Davis & Co | 1, 5-diarylpyrrole-2-propionic acid compounds |
FR1393615A (fr) | 1964-03-05 | 1965-03-26 | Inst Organiycheskoi Khim Im N | Procédé de préparation de la nu-vinylpyrrolidone |
US3427305A (en) * | 1966-11-01 | 1969-02-11 | Searle & Co | 5 - ((halo/alkoxy)phenyl) - 1 - (p - sulfonamido(phenyl/benzyl)) - 2 - pyrrolepropionic acids |
US3752826A (en) * | 1970-01-26 | 1973-08-14 | Mcneilab Inc | Aroyl substituted pyrroles |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4694018A (en) * | 1985-11-29 | 1987-09-15 | G. D. Serale & Co. | Substituted 1,5-diphenyl-2-pyrrolepropionic acids and derivatives |
US4792568A (en) | 1986-04-14 | 1988-12-20 | Rorer Pharmaceutical Corporation | Aryl pyrroles as useful antiallergy compounds |
US4826869A (en) | 1988-02-19 | 1989-05-02 | Syntex (U.S.A.) Inc. | N-(lower alkyl)-2-(3'ureidobenzyl)pyrrolidines |
US5189051A (en) | 1990-05-10 | 1993-02-23 | E. I. Du Pont De Nemours And Company | Treatment of glaucoma and ocular hypertension with pyrrole angiotensin-II receptor antagonists |
DE4036706A1 (de) | 1990-11-17 | 1992-05-21 | Hoechst Ag | Verfahren zur behandlung der cardialen sowie der vasculaeren hypertrophie und hyperplasie |
US6008368A (en) | 1993-04-28 | 1999-12-28 | G. D. Searle & Co. | Pharmaceutical compositions for treatment of circulatory disorders using N-substituted (α-imidazolyl-toluyl) pyrrole aniotensin II antagonists |
US5187271A (en) | 1991-02-28 | 1993-02-16 | G. D. Searle & Co. | N-substituted (α-imidazolyl-toluyl) pyrrole compounds for treatment of circulatory disorders |
US5451597A (en) | 1993-05-27 | 1995-09-19 | G.D. Searle & Co. | Treatment of circulatory disorders using n-substituted (α-imidazolyl-toluyl) pyrrole angiotensin II antagonists |
US5840751A (en) | 1993-11-19 | 1998-11-24 | Warner-Lambert Company | 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents |
US6057367A (en) | 1996-08-30 | 2000-05-02 | Duke University | Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses |
EP0952828B1 (en) | 1996-11-13 | 2006-08-16 | Cold Spring Harbor Laboratory | Therapeutic uses for nitric oxide inhibitors |
ATE250576T1 (de) | 1996-12-10 | 2003-10-15 | Searle & Co | Substituierte pyrrolylverbindungen zur behandlung von entzündungen |
FR2782720B1 (fr) | 1998-09-01 | 2001-10-12 | Oreal | Utilisation en teinture capillaire de condensats de quinoline-5,8-diones ou de quinoxaline-5,8-diones et de pyrroles, anilines ou indoles substitues |
US6355812B1 (en) * | 1999-06-11 | 2002-03-12 | Orth-Mcneil Pharmaceutical, Inc. | Methods for the synthesis of dioxoalkanoic acid compounds |
US6589978B2 (en) * | 2000-06-30 | 2003-07-08 | Hoffman-La Roche Inc. | 1-sulfonyl pyrrolidine derivatives |
US6359182B1 (en) | 2000-10-26 | 2002-03-19 | Duke University | C-nitroso compounds and use thereof |
US7049308B2 (en) | 2000-10-26 | 2006-05-23 | Duke University | C-nitroso compounds and use thereof |
US7179791B2 (en) | 2001-01-11 | 2007-02-20 | Duke University | Inhibiting GS-FDH to modulate NO bioactivity |
EP1405636A4 (en) | 2001-06-26 | 2009-04-15 | Takeda Pharmaceutical | REGULATOR OF RECTINTOR FUNCTION RELATING TO RETINOIDS |
GB0119172D0 (en) | 2001-08-06 | 2001-09-26 | Melacure Therapeutics Ab | Phenyl pyrrole derivatives |
GB0212785D0 (en) | 2002-05-31 | 2002-07-10 | Glaxo Group Ltd | Compounds |
US7186716B2 (en) | 2002-08-12 | 2007-03-06 | Sugen, Inc. | 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors |
GB0229581D0 (en) | 2002-12-19 | 2003-01-22 | Cyclacel Ltd | Use |
US20060270628A1 (en) | 2003-04-29 | 2006-11-30 | Jagattaran Das | Antiinfective 1,2,3-triazole derivatives, process for their preparation and pharmaceutical compositions containing them |
AU2004251690A1 (en) | 2003-06-04 | 2005-01-06 | Duke University | Compositions and methods for modulating S-nitrosoglutathione reductase |
CN1679552A (zh) | 2004-03-15 | 2005-10-12 | 永信药品工业股份有限公司 | 优先抑制促炎细胞因子的释放 |
MY144903A (en) | 2004-06-17 | 2011-11-30 | Novartis Ag | Pyrrolopyridine derivatives and their use as crth2 antagonists |
PT1773768T (pt) | 2004-07-30 | 2018-11-30 | Exelixis Inc | Derivados de pirrol como agentes farmacêuticos |
CN101006052B (zh) | 2004-07-30 | 2013-11-06 | 埃克塞利希斯股份有限公司 | 作为药用制剂的吡咯衍生物 |
FR2881426B1 (fr) | 2005-02-03 | 2007-03-30 | Aventis Pharma Sa | Pyrolles et imidazoles substitues, compositions les contenant, procede de frabrication et utilisation |
JP2006290791A (ja) | 2005-04-11 | 2006-10-26 | Astellas Pharma Inc | アゾール置換スルホニルベンゼン誘導体 |
WO2006133926A1 (en) | 2005-06-17 | 2006-12-21 | Carex Sa | Pyrazole derivates as cannabinoid receptor modulators |
WO2006138744A2 (en) | 2005-06-24 | 2006-12-28 | Genelabs Technologies, Inc. | Heteroaryl derivatives for treating viruses |
US20090176837A1 (en) | 2005-07-12 | 2009-07-09 | Sony Corporation | Compounds with activity at retinoic acid receptors |
JP2011507811A (ja) * | 2007-12-13 | 2011-03-10 | インディアナ・ユニバーシティ・リサーチ・アンド・テクノロジー・コーポレーション | 哺乳動物のs−ニトロソグルタチオンレダクターゼを阻害するための材料および方法 |
EP2297183A4 (en) | 2008-05-09 | 2012-07-04 | Univ Duke | AT THE DISCOVERY THIOREDOXIN CONTAINS STAIN OXIDE RELIEF IN CELLS, BASED TREATMENT OF DISEASES |
WO2010019905A1 (en) | 2008-08-15 | 2010-02-18 | N30 Pharmaceuticals, Llc | Novel pyrrole inhibitors of s-nitrosoglutathione reductase as therapeutic agents |
HUE031580T2 (en) | 2008-08-15 | 2017-07-28 | Nivalis Therapeutics Inc | New pyrrole inhibitors of S-nitrosoglutathion reductase as therapeutic agents |
JP5524209B2 (ja) | 2008-08-15 | 2014-06-18 | エヌサーティー・ファーマシューティカルズ・インコーポレーテッド | S−ニトロソグルタチオンレダクターゼのピロール阻害剤 |
WO2010107476A1 (en) | 2009-03-19 | 2010-09-23 | Duke University | Inhibiting gsnor |
EP2512247B1 (en) | 2009-12-16 | 2014-06-04 | N30 Pharmaceuticals, Inc. | Novel thiophene inhibitors of s-nitrosoglutathione reductase |
US20140113945A1 (en) | 2011-07-05 | 2014-04-24 | N30 Pharmaceuticals, Inc. | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents for Liver Toxicity |
-
2009
- 2009-08-14 HU HUE09807378A patent/HUE031580T2/en unknown
- 2009-08-14 JP JP2011523200A patent/JP2012500216A/ja not_active Withdrawn
- 2009-08-14 DK DK09807383.6T patent/DK2315591T3/en active
- 2009-08-14 EP EP16150296.8A patent/EP3069721A1/en not_active Withdrawn
- 2009-08-14 BR BRPI0917017A patent/BRPI0917017B8/pt not_active IP Right Cessation
- 2009-08-14 WO PCT/US2009/053931 patent/WO2010019910A1/en active Application Filing
- 2009-08-14 ES ES09807378.6T patent/ES2610158T3/es active Active
- 2009-08-14 SI SI200931431A patent/SI2315591T1/sl unknown
- 2009-08-14 ES ES09807383.6T patent/ES2572615T3/es active Active
- 2009-08-14 CA CA2734154A patent/CA2734154C/en active Active
- 2009-08-14 AU AU2009281747A patent/AU2009281747B2/en not_active Ceased
- 2009-08-14 PL PL09807383.6T patent/PL2315591T3/pl unknown
- 2009-08-14 PT PT98073786T patent/PT2318006T/pt unknown
- 2009-08-14 CN CN2009801410890A patent/CN102186478B/zh active Active
- 2009-08-14 DK DK09807378.6T patent/DK2318006T3/en active
- 2009-08-14 HU HUE09807383A patent/HUE027659T2/en unknown
- 2009-08-14 EP EP09807378.6A patent/EP2318006B1/en active Active
- 2009-08-14 JP JP2011523205A patent/JP2012500219A/ja active Pending
- 2009-08-14 US US13/057,220 patent/US8673961B2/en active Active
- 2009-08-14 KR KR20117005976A patent/KR20110042364A/ko not_active Application Discontinuation
- 2009-08-14 WO PCT/US2009/053923 patent/WO2010019903A1/en active Application Filing
- 2009-08-14 PL PL09807378T patent/PL2318006T3/pl unknown
- 2009-08-14 RU RU2011109339/04A patent/RU2500668C2/ru not_active IP Right Cessation
- 2009-08-14 LT LTEP09807378.6T patent/LT2318006T/lt unknown
- 2009-08-14 EP EP09807383.6A patent/EP2315591B1/en active Active
- 2009-08-14 SI SI200931581A patent/SI2318006T1/sl unknown
- 2009-08-14 US US13/057,171 patent/US8691816B2/en not_active Expired - Fee Related
-
2011
- 2011-02-03 IL IL211056A patent/IL211056A/en not_active IP Right Cessation
- 2011-02-07 ZA ZA2011/00966A patent/ZA201100966B/en unknown
- 2011-10-14 HK HK11111007.5A patent/HK1156540A1/zh not_active IP Right Cessation
- 2011-10-18 HK HK11111135.0A patent/HK1156846A1/zh not_active IP Right Cessation
-
2014
- 2014-02-05 US US14/173,377 patent/US8957105B2/en not_active Expired - Fee Related
- 2014-03-11 US US14/204,849 patent/US9138427B2/en not_active Expired - Fee Related
- 2014-10-20 JP JP2014213744A patent/JP5917650B2/ja not_active Expired - Fee Related
- 2014-10-20 JP JP2014213583A patent/JP2015038132A/ja active Pending
-
2015
- 2015-01-15 US US14/598,062 patent/US9180119B2/en not_active Expired - Fee Related
- 2015-10-26 US US14/922,928 patent/US9498466B2/en active Active
-
2016
- 2016-05-18 CY CY20161100428T patent/CY1117524T1/el unknown
- 2016-06-13 HR HRP20160658TT patent/HRP20160658T1/hr unknown
- 2016-06-16 SM SM201600177T patent/SMT201600177B/it unknown
- 2016-11-08 US US15/345,767 patent/US9814700B2/en active Active
-
2017
- 2017-01-09 HR HRP20170019TT patent/HRP20170019T1/hr unknown
- 2017-01-10 CY CY20171100029T patent/CY1118454T1/el unknown
- 2017-01-19 SM SM201700037T patent/SMT201700037B/it unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2610158T3 (es) | Nuevos inhibidores pirrólicos de S-nitrosoglutatión reductasa como agentes terapéuticos | |
AU2009265362B2 (en) | Chemical compounds 251 | |
AU2007351498B2 (en) | Organic compounds | |
AU2010311299C1 (en) | Androgen receptor modulating compounds | |
US8124610B2 (en) | Sodium channel inhibitors | |
KR101867110B1 (ko) | 트라이아진 유도체 및 그것을 함유하는 진통 작용을 갖는 의약 조성물 | |
JP5378532B2 (ja) | 複素環γ−セクレターゼモジュレーター | |
EP2822931B1 (en) | Triazolone compounds and uses thereof | |
AU2007230346B2 (en) | Triazolone derivative | |
CA2747419A1 (en) | Sulfonamide derivatives | |
CA2592116A1 (en) | Anti-inflammatory medicaments | |
CA2620179A1 (en) | Inhibitors of voltage-gated sodium channels | |
AU2006261841A1 (en) | Pyrazole based LXR modulators | |
AU2014291142A1 (en) | Cyanotriazole compounds | |
AU2006242824A1 (en) | Antimicrobial agents | |
JPS61254589A (ja) | 7−置換二環系ピラゾリジノン類 | |
AU2009257795A1 (en) | Pyrazole derivatives useful as inhibitors of FAAH | |
AU2008319719A1 (en) | Heterocyclic compound and pharmaceutical composition thereof | |
JP2013517273A5 (es) | ||
WO2008039023A1 (en) | Heteroaryl-pyrazole derivatives as cannabinoid cb1 receptor antagonists | |
WO2004089937A1 (ja) | 7員複素環誘導体 | |
CA2904142A1 (en) | Pyrazole derivative having a xanthine oxidase inhibitory activity | |
KR20180080187A (ko) | 디메톡시벤질기의 탈리 방법 |